A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Healthy, Alzheimer Disease

In brief

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study in Healthy Adults and Open-label Single Dose Study in Patients with Alzheimer's Disease to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VG-3927.

Key facts

Study ID

NCT06343636

Run by

Vigil Neuroscience, Inc.

People needed

115

Starts

2023-09-22

Expected to finish

2025-01-10

Last updated by the study team

2025-02-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• The participant is deemed healthy by the principal investigator, as determined by prestudy medical evaluation
• The participant voluntarily agrees to participate in this study and signs an institutional review board approved informed consent

You may not qualify if…

• The participant has any concurrent disease or condition that, in the opinion of the principal investigator, would make the participant unsuitable for participation in the clinical study

Where it is running

• K2 Medical Research — Maitland, Florida, United States
• Clinical Pharmacology of Miami — Miami, Florida, United States
• Nucleus Network — Melbourne, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.